US EditionMerck's Oral Cholesterol Pill Cuts LDL by 60% in Trial
Merck’s oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by about 60% after 24 weeks and sustained reductions through one year in a trial of 2,912 adults with or at risk for ASCVD.
- On Saturday at the American Heart Association meeting, Merck, pharmaceutical company, reported enlicitide reduced LDL by up to 60% after 24 weeks in a phase 3 trial of 2,912 adults.
- Amid widespread under‑treatment of LDL cholesterol, about 70 patients on lipid‑lowering therapies do not reach guideline goals, and PCSK9 injectables face barriers with list prices over $500 a month.
- Merck reported that safety signals were similar, with about 10% of enlicitide patients experiencing serious adverse events and Dr. Puja Banka stating `Ultimately, the side effects were balanced between the enlictide arm and the placebo arm`.
- Merck plans to apply to the US Food and Drug Administration for enlicitide early next year and aims to launch the drug in 2027 while making it affordable to 'democratize PCSK9' access.
- A larger outcomes study of more than 14,500 people is underway as PCSK9 blockade can reduce heart attacks and strokes by up to 20%, with at least 6 million adults in the United States eligible.
36 Articles
36 Articles
It's called enlicithide and it'll take one tablet a day to halve Ldl levels. A breakthrough is expected for millions of patients. That's how I work...
Investigational daily pill lowered bad cholesterol as much as injectables
Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an effective alternative to injections of PCSK9 inhibitors to lower low-density lipoprotein (LDL or "bad" cholesterol), according to a preliminary late-breaking science presentation Saturday at the American Heart Association's Scientific Sessions 2025. The meeting, held Nov. 7–10 in New Orleans, is a premier global exchange of …
Merck's Enlicitide Shows Promising Results In Phase 3 CORALreef Lipids Trial
(RTTNews) - Merck & Co Inc. (MRK) has unveiled the first results from its pivotal Phase 3 CORALreef Lipids trial, highlighting the efficacy of enlicitide decanoate, an investigational once-daily oral PCSK9 inhibitor. The treatment demonstrated a statistically significant and clin
Coverage Details
Bias Distribution
- 68% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
